CLOSED
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%

Search & Analyze

Popular Searches

Lupin Ltd.

HealthcarePharmaceuticals & Drugs
www.lupin.comBSE: 500257NSE: LUPIN
₹1,925.00BSE0.16%

23 Oct, 4:01 PM

₹1,925.00
₹88.03K Cr
15.92
3.70
27.11%
₹1,928.60
₹1,893.25
₹2,530.00
₹1,893.25

Customise metrics bar

Lupin Ltd. (LUPIN) share price closed at ₹1,925.00 on the BSE on Friday, October 23, 2026, down by 0.16% from its of ₹1,928.00. In that session LUPIN reached a of 1,928.60 and of 1,893.25. The for the session was 1,912.68. The stands at 2,090.34 and is at 2,246.52. Looking at , the stock ended the session moving sideways.

Stock Overview

Symbol

LUPIN

₹1,921.10

₹1,928.00

₹1,912.68

₹2,090.34

Price 7.91% below

₹2,246.52

Price 14.31% below

89.82% of range
₹1,893.25₹1,928.60
4.99% of range
₹1,893.25₹2,530.00

Price Performance

Peer Comparison

Name
SUN PHARMA.

SUNPHARMA

1,743.0034.584,18,204.090.922,901.2326.53%15,299.8810.46%19.11
DIVI'S LAB.

DIVISLAB

8,984.0081.542,38,496.970.33902.0065.50%3,080.0027.80%21.51
TORRENT PHAR

TORNTPHARM

4,482.0080.261,70,480.870.85534.00-9.64%4,979.0050.79%19.27
ZYDUSLIFE

ZYDUSLIFE

1,127.8524.931,12,503.470.09990.20-34.90%8,017.0021.96%21.39
CIPLA LTD.

CIPLA

1,337.0032.041,08,012.300.97785.55-39.18%7,119.282.33%16.00
LAURUSLABS

LAURUSLABS

1,974.0097.551,06,657.630.10362.07123.94%2,026.3129.10%18.20
DR.REDDY'S

DRREDDY

1,224.5036.501,02,206.600.65913.20-31.69%8,697.80-1.48%13.75
Lupin Ltd.

LUPIN

1,925.0015.9288,028.320.941,416.9816.01%8,276.8932.04%28.86

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

ParticularsJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
5,600.335,672.735,767.715,667.136,268.347,047.517,167.527,474.668,276.89
Expenses4,359.364,332.374,411.814,345.964,541.104,706.184,905.674,989.085,827.34
1,240.971,340.361,355.901,321.171,727.242,341.332,261.852,485.582,449.55
22.16%23.63%23.51%23.31%27.55%33.22%31.56%33.25%29.60%
67.7842.2953.7156.9579.0490.00-311.879.37130.32
Interest68.0170.8766.8989.1091.76107.59114.98120.16109.64
247.71256.92271.45393.18298.98316.77312.96446.79452.85
993.031,054.861,071.27895.841,415.542,006.971,522.041,928.002,017.36
18.88%18.52%19.83%12.67%13.71%26.02%22.44%23.82%29.76%
801.31852.63855.16772.521,219.031,477.921,175.551,460.341,415.00
17.5718.6918.7416.9226.6932.3525.7331.9430.95

Profit & Loss

consolidated figures in ₹ Crores · Annual

ParticularsFY 2021-22 (Mar)FY 2022-23 (Mar)FY 2023-24 (Mar)FY 2024-25 (Mar)FY 2025-26 (Mar)
No of Months12.0012.0012.0012.0012.00
INCOME :
29,676.3928,445.9031,737.4937,186.9343,111.99
16,405.4816,641.6620,010.8222,707.9027,958.03
EXPENDITURE :
Increase/Decrease in Stock-198.32153.73-457.44-257.78-162.45
Raw Material Consumed5,979.165,870.166,102.106,075.966,488.04
Power & Fuel Cost443.96479.68493.07479.09461.55
Employee Cost2,989.303,087.153,494.573,964.204,574.53
Other Manufacturing Expenses2,187.992,176.132,738.393,006.403,343.42
General and Administration Expenses3,490.621,733.072,221.052,514.002,931.35
Selling and Distribution Expenses1,096.101,188.721,343.301,417.191,853.97
Miscellaneous Expenses201.43232.45286.67231.32308.09
16,190.2414,921.0916,221.7117,430.3819,798.50
Operating Profit (Excl OI)215.241,720.573,789.115,277.528,159.53
213.67150.91141.58201.611,080.92
428.911,871.483,930.695,479.139,240.45
Interest142.77274.30311.61294.87434.49
PBDT286.141,597.183,619.085,184.268,805.96
1,658.71880.691,196.811,169.261,375.50
Profit Before Taxation & Exceptional Items-1,372.57716.492,422.274,015.007,430.46
Exceptional Income / Expenses-557.91
-1,372.21716.492,422.274,015.006,872.55
Provision for Tax137.15268.80486.70708.741,517.08
-1,509.36447.691,935.573,306.265,355.47
Extra items0.000.00
Minority Interest-18.68-17.61-21.09-24.64-22.63
Consolidated Net Profit-1,528.04430.081,914.483,281.625,332.84
Profit Balance B/F11,108.329,288.429,535.9511,183.3714,070.57
Appropriations9,580.289,718.5011,450.4314,464.9919,403.41
Equity Dividend %200.00%200.00%400.00%600.00%900.00%
-33.629.4542.0171.87116.64
Adjusted EPS-33.629.4542.0171.87116.64

Balance Sheet

consolidated figures in ₹ Crores

ParticularsFY 2021-22 (Mar)FY 2022-23 (Mar)FY 2023-24 (Mar)FY 2024-25 (Mar)FY 2025-26 (Mar)
90.9091.0091.1491.3291.44
Share Warrants & Outstandings161.73148.94114.4583.9864.20
Total Reserves11,900.6412,224.5614,084.7017,028.2022,292.63
Reserve excluding Revaluation Reserve11,900.6412,224.5614,084.7017,028.2022,292.63
Revaluation reserve0.000.00
12,153.2712,464.5014,290.2917,203.5022,448.27
Minority Interest68.7178.3283.1690.8565.10
Secured Loans141.861,196.481,327.35
Unsecured Loans27.51569.75316.04
Deferred Tax Assets / Liabilities71.1073.78-56.66-332.69-345.95
Other Long Term Liabilities607.12547.77500.96520.42805.36
Long Term Provisions332.99343.03375.40436.08532.70
Total Non-Current Liabilities1,153.07992.09819.702,390.042,635.50
Trade Payables2,282.912,531.532,958.112,958.164,173.13
Other Current Liabilities1,394.111,577.221,919.402,274.323,300.05
Short Term Borrowings3,702.304,216.542,669.913,015.563,948.78
Short Term Provisions897.12940.08954.08713.351,229.28
Total Current Liabilities8,276.449,265.378,501.508,961.3912,651.24
Total Liabilities21,651.4922,800.2823,694.6528,645.7837,800.11
Gross Block15,990.3018,077.4219,664.6920,183.6923,217.39
Less: Accumulated Depreciation8,608.689,722.1810,653.9810,464.3412,137.78
Less: Impairment of Assets132.4185.73
Net Block7,381.628,355.248,878.309,719.3510,993.88
Capital Work in Progress847.47894.82595.67355.45695.16
Non Current Investments77.6077.13227.7087.2792.54
Long Term Investment77.6077.13227.7087.2792.54
Long Term Loans & Advances572.41620.92320.65307.83301.79
Other Non Current Assets15.9057.7047.821,216.111,368.41
Total Non-Current Assets9,193.8110,348.9810,247.0011,847.2013,772.73
Currents Investments822.40439.77846.931,059.113,577.13
Inventories4,630.734,491.764,953.905,476.356,083.25
Sundry Debtors4,261.944,480.704,692.055,497.106,604.06
Cash and Bank1,098.131,293.131,202.543,142.335,652.90
Other Current Assets497.541,519.981,428.051,311.061,670.34
Short Term Loans and Advances1,146.94225.96324.18312.63439.70
Total Current Assets12,457.6812,451.3013,447.6516,798.5824,027.38
Net Current Assets (Including Current Investments)4,181.243,185.934,946.157,837.1911,376.14
Total Assets21,651.4922,800.2823,694.6528,645.7837,800.11
Contingent Liabilities668.79943.93860.70780.831,094.02
Total Debt3,844.164,244.052,669.915,076.655,910.20
263.84270.67311.08374.93489.59
Adjusted Book Value263.84270.67311.08374.93489.59

Cash Flow

consolidated figures in ₹ Crores

ParticularsFY 2021-22 (Mar)FY 2022-23 (Mar)FY 2023-24 (Mar)FY 2024-25 (Mar)FY 2025-26 (Mar)
No of Months12.0012.0012.0012.0012.00
-1,372.21716.492,422.274,015.006,872.55
Adjustment1,707.681,097.411,466.631,301.521,095.61
Changes In working Capital-15.04326.5285.51-1,410.54633.69
Cash Flow after changes in Working Capital320.432,140.423,974.413,905.988,601.85
Cash Flow from Operating Activities367.311,897.243,648.362,999.947,334.50
Cash Flow from Investing Activities1,292.23-1,286.77-1,712.20-4,171.89-3,864.59
Cash Flow from Financing Activitie-1,572.32-337.25-2,184.211,731.88-845.87
Net Cash Inflow / Outflow87.22273.22-248.05559.932,624.04
Opening Cash & Cash Equivalents926.22991.371,231.81983.761,543.69
Closing Cash & Cash Equivalent1,013.441,264.59983.761,543.694,167.73

Ratios

Valuation

15.92
3.70
8.82
2.98
120.90
520.48

Profitability

27.11
28.86
16.12
18.93
12.42

Leverage & Liquidity

0.26
1.90
16.82

Returns

0.94
1.30

Shareholding Pattern

Numbers in percentages

ParticularsJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
46.9846.9646.9546.9246.9046.9046.8946.8646.8546.84
46.1046.6046.7946.8846.8147.0647.0747.0347.0747.06
6.926.446.266.206.286.066.036.116.086.09
53.0253.0453.0553.0853.1053.1053.1153.1453.1553.16
No. of Shareholders2,88,5372,79,2802,81,9882,83,2102,86,6042,80,2562,88,9312,90,4113,00,2832,97,301

Mutual Funds Invested(250)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 138 active funds hold 13.89% in Lupin Ltd., contributing to ₹12.89K Cr of holdings

FundAs of
HD
HDFC Balanced Advantage Fund - Growth - Direct PlanHybrid - Balanced Advantage
1,154.461.1356,86,457Sep '26
HD
HDFC Flexi Cap Fund - Growth - Direct PlanFlexi Cap Fund
992.540.9148,88,886Sep '26
HD
HDFC Large Cap Fund - Growth - Direct PlanLarge Cap Fund
937.142.5146,15,980Sep '26
MI
Mirae Asset Large & Midcap Fund - Growth - Direct PlanLarge & Mid Cap
799.721.8739,39,111Sep '26
MI
Mirae Asset Midcap Fund - Growth - Direct PlanMid Cap Fund
653.333.3432,18,048Sep '26
NI
Nippon India Pharma Fund - Growth - Direct PlanPharma & Health Care
565.216.1727,83,991Sep '26
NI
Nippon India Growth Mid Cap Fund - Growth Option - Direct PlanMid Cap Fund
446.640.8922,00,000Sep '26
KO
Kotak Arbitrage Fund - Growth - Direct PlanHybrid - Arbitrage Fund
445.400.5921,93,850Sep '26
SB
SBI Midcap Fund - Growth - Direct PlanMid Cap Fund
426.341.8321,00,000Sep '26
NI
Nippon India Large Cap Fund - Growth - Direct PlanLarge Cap Fund
401.650.7819,78,374Sep '26

Corporate Actions

Showing: All
DateTypeDetailsEx-DateRecord Date
2026-10-19Board Meeting Quarterly Results
2026-07-22Board Meeting Quarterly Results
2026-07-08AGM

Insider Trading

DatePersonCategoryTransaction TypeSharesValue (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Lupin Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Company Information

Industry

Pharmaceuticals & Drugs

Founded

1983

Headquarters

Mumbai, Maharashtra

Group

Lupin

Chairman

Manju D Gupta

Managing Director

Nilesh Gupta

Company Secretary

Amit Kumar Gupta

Face Value

₹2

CIN

L24100MH1983PLC029442

Get in Touch

Websitewww.lupin.com
Emailinfo@lupin.com
Phone022 66402323

Key Management

11 members across the board and senior leadership

Amit Kumar Gupta

Company Secretary & Compliance Officer

Manju D Gupta

Chairperson

Nilesh Gupta

Managing Director

Ramesh Swaminathan

Executive Director, Global CFO, Head of IT and API Plus SBU

Jeffrey Kindler

Non Executive Independent Director

Anand Kripalu

Non Executive Independent Director

Punita Kumar Sinha

Non Executive Independent Director

Punita Lal

Non Executive Independent Director

K B S Anand

Non Executive Independent Director

Mark D McDade

Non Executive Independent Director

Alfonso Zulueta

Non Executive Independent Director

LUPIN Latest News

News

10 of 10 articles
EQUITY9 Oct 2026 · 09:41

Lupin moves up on getting USFDA’s approval for Phytonadione Injectable Emulsion

Phytonadione Injectable is indicated for the treatment and prophylaxis of hypoprothrombinemia (low blood clotting) and vitamin K-deficiency

COMPANY9 Oct 2026 · 09:15

Lupin gets USFDA’s approval for Phytonadione Injectable Emulsion

Phytonadione Injectable is indicated for the treatment and prophylaxis of hypoprothrombinemia (low blood clotting) and vitamin K-deficiency

EQUITY6 Oct 2026 · 11:05

Lupin informs about press release

EQUITY6 Oct 2026 · 10:50

Lupin inches up on launching world’s first triple combination drug ‘Formoflo-G MDI’ for COPD in India

The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India

COMPANY6 Oct 2026 · 10:41

Lupin launches world’s first triple combination drug ‘Formoflo-G MDI’ for COPD in India

The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India

EQUITY28 Sept 2026 · 11:48

Lupin informs about press release

COMPANY28 Sept 2026 · 09:42

Lupin gets USFDA’s tentative nod for Novel Apixaban Oral Suspension

Upon final approval, the product will be manufactured at the company’s Somerset, New Jersey facility

EQUITY17 Aug 2026 · 15:03

Lupin rises on getting USFDA’s final nod for Pitolisant Tablets

The USFDA has approved the company’s Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix for the indications in the approved labelling

COMPANY17 Aug 2026 · 14:51

Lupin gets USFDA’s final nod for Pitolisant Tablets

The USFDA has approved the company’s Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix for the indications in the approved labeling

COMPANY10 Aug 2026 · 18:14

Lupin gets USFDA’s nod for Sodium Zirconium Cyclosilicate for Oral Suspension in US

Sodium Zirconium Cyclosilicate for Oral Suspension (RLD Lokelma) had estimated annual sales of $568 million in the U.S

LUPIN

₹1,925.00

-0.16%